BlossomHill Therapeutics Inc. (BLSM)
BLSM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BLSM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0001839970 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $224.9M cash; operating cash flow -$16.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 31,784,909 (2026-11-10). | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Diego, California, United States | PCAOB Form AP 2026-08-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $15.2M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$24.0M | -$22.2M | $224.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$23.8M | Not filed | $95.4M | No debt tags | Needs four quarters | 10-Q 2026-09-18 |
| Q3 2026 2025-09-30 | Not filed | -$16.0M | -$11.6M | $67.8M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2025-06-30 | Not filed | -$13.2M | Not filed | $79.1M | No debt tags | Needs four quarters | 10-Q 2026-09-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-08-07 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 48 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.9% |
| 1 month | -9.4% |
| 3 months | -14.3% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -47.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CTMX | CytomX Therapeutics Inc. | $1.99 | -2.70% | $432.7M |
| ASMB | Assembly Biosciences Inc. | $21.29 | +0.80% | $436.0M |
| EOLS | Evolus Inc. | $6.63 | -4.74% | $438.8M |
| AVTX | Avalo Therapeutics Inc. | $7.37 | -5.03% | $426.2M |
| ARVN | Arvinas Inc. | $6.77 | -0.73% | $443.3M |
| MPLT | MapLight Therapeutics Inc. | $6.90 | -4.83% | $446.9M |
| DMAC | DiaMedica Therapeutics Inc. | $8.33 | -5.23% | $449.5M |
| OVID | Ovid Therapeutics Inc. | $2.40 | -5.51% | $453.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier